[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640530":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":46,"responsibleParty":64,"collaborators":26,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":26,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":26,"enrollmentInfo":75,"targetDuration":26,"studyType":78,"phases":79,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":98,"whyStopped":26,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"University of Nebraska","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A: boost to prostate alone","ACTIVE_COMPARATOR","Participants assigned to Arm A will receive external beam radiation therapy consisting of 3625 cGy to the planning target volume (PTV), plus a boost of 4000 cGy to the clinical target volume (CTV), consisting of the prostate alone without a margin. Treatment will be delivered over 5 fractions with at least 36 hours between fractions via simultaneous integrated boost (SIB).",[13],"Radiation: Prostate stereotactic body radiotherapy with whole gland boost",{"label":15,"type":16,"description":17,"interventionNames":18},"Arm B: boost to dominant intra-prostatic lesion (DIL)","EXPERIMENTAL","Participants assigned to Arm B will receive external beam radiation therapy consisting of 3625 cGy to the planning target volume (PTV), plus a boost of 4500 cGy to the dominant intra-prostatic lesion (DIL). Treatment will be delivered over 5 fractions with at least 36 hours between fractions via simultaneous integrated boost (SIB).",[19],"Radiation: Prostate stereotactic body radiotherapy with DIL boost",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"RADIATION","Prostate stereotactic body radiotherapy with whole gland boost","External beam radiation therapy delivered via linear accelerator-based SBRT using simultaneous integrated boost",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Prostate stereotactic body radiotherapy with DIL boost","External beam radiation therapy delivered via linear accelerator-based SBRT using simultaneous integrated boost to the dominant intra-prostatic lesion.",[15],[32],{"name":33,"affiliation":34,"role":35},"Michael Baine, MD, PhD","University of Nebraska medicine","PRINCIPAL_INVESTIGATOR",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},"Krishna Gottipati, MS","CONTACT","4025593518","krgottipati@unmc.edu",{"name":43,"role":39,"phone":44,"phoneExt":26,"email":45},"IIT Office Gottipati","4025590963","IITOFFICE@unmc.edu",[47],{"facility":48,"status":26,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Fred & Pamela Buffet Cancer Center","Omaha","Nebraska","68198","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-95.94043,41.25626,{"lat":58,"lon":57},[61],{"name":33,"role":39,"phone":62,"phoneExt":26,"email":63},"(402) 552-2703","mbaine@unmc.edu",{"type":65,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100640530","phase-2-whole-versus-partial-gland-boost-during-prostate-sbrt-100640530",false,"NCT07574489","Whole Versus Partial Gland Boost During Prostate SBRT","Whole Versus Partial Gland Boost During Prostate SBRT (Gland Boost)","Inclusion Criteria:\n\n1. Adults ≥19 years of age\n2. Patients with a diagnosis of prostate adenocarcinoma for which stereotactic body radiotherapy (SBRT) to the prostate ± proximal seminal vesicles is being offered\n3. Prostate gland volume \\\u003C100 cc prior to initiation of androgen deprivation therapy (ADT), as reported at time of biopsy or by imaging (e.g., ultrasound, MRI, or CT)\n4. PI-RADS 4 or 5 lesion seen on pre-treatment MRI\n5. IPSS\u002FAUA symptom score less than 16\n\nExclusion Criteria:\n\n1. Prior treatment for prostate cancer\n2. Prior solid cancer diagnosis within the last 5 years\n3. Any history of anal or rectal cancer\n4. Any history of invasive carcinoma of the bladder\n5. History of prior circumferential resection of the rectum (such as LAR or APR)","MALE","19 Years",{"count":76,"type":77},186,"ESTIMATED","INTERVENTIONAL",[80,81],"PHASE2","PHASE3","This phase 2\u002F3 randomized trial evaluates whether dose escalation to the dominant intra-prostatic lesion (DIL) compared to whole gland dose escalation during prostate stereotactic body radiotherapy (SBRT) results in differences in genitourinary (GU) and gastrointestinal (GI) toxicities.",[84,85],"Prostate Cancer","Prostate Adenocarcinoma",[87,88,89,90,91,92,93,94,95,96,97],"Prostate SBRT","Stereotactic Body Radiotherapy","Dose Escalation","Dominant Intraprostatic Lesion","DIL","Radiation Therapy","Genitourinary Toxicity","Gastrointestinal Toxicity","CTCAE","RTOG","EPIC","NOT_YET_RECRUITING","2026-06-25",{"date":101,"type":102},"2026-06-29","ACTUAL",{"date":104,"type":77},"2026-07-25",{"date":106,"type":77},"2035-08-25",{"name":5,"class":6},1]